Structure's obesity pill shows up to 16.3% weight loss in study
16/03/2026 11:04
March 16 (Reuters) - Structure Therapeutics GPCR.O said its oral obesity drug aleniglipron delivered up to 16.3% weight loss, when compared with a placebo after 44 weeks of treatment in a mid‑stage study. (Reporting by Sahil Pandey and Puyaan Singh in Bengaluru; Editing by Sahal Muhammed) ((Sahil.Pandey@thomsonreuters.com;))
Recent news on Structure Therapeutics
See all newsFactbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Structure falls as investors await more obesity trial data, says Jefferies